GEN Exclusives

More »

Feature Articles

More »
Dec 1, 2009 (Vol. 29, No. 21)

Big Pharma's Interest in Vaccine Products on Rise

Pipeline Gap Could Be Remedied by Recent Innovations and Fruitful Biotechnology Partnerships

  • Big pharma faces a patent cliff in 2012 when around $90 billion in revenue could be lost to generics. The companies that are going to weather this storm have to look at other revenue streams. Vaccine development is gaining a lot of attention because it has an attractive adjacency to many pharmaceutical companies’ existing R&D, manufacturing capacity, regulatory expertise, and customer base.

    Additionally, producing vaccines is the kind of activity that lends itself well to collaborative partnerships, explained Franz-Robert Klingan, Ph.D., partner at Bain & Company, at the recent “World Vaccine Congress” in Lyon.

    Traditionally, several major pharmas have been heavily invested in vaccine production including sanofi-aventis, GlaxoSmithKline, Merck and Wyeth (now part of Pfizer). Novartis became a major producer with the acquisition of Chiron in 2006. Many factors are persuading other big players to enter the vaccine fray with gusto, including the lack of corresponding vaccines for over 40 different pathologies and the significant potential of therapeutic vaccines.

    “Three years ago we were not viewed as being in the vaccine business,” Rob Sinclair, director of worldwide business development at Pfizer, said. “We’re catching up now as a result of the acquisition of PowderMed in 2006 and Coley Pharmaceuticals in 2007. We now have access to DNA vaccine technology and a TLR9 adjuvant. We also licensed CDX-110, an immunotherapy to treat malignant glioblastoma, from Celldex Therapeutics in 2008 and virus-like particle technology from Cytos this year.”

    The vaccine market is also proving attractive to biotechs because the development cycle for vaccines is often much shorter than for therapeutics. “Biotechs can contribute innovation that pharmas need,” explained Katherine Cohen, Ph.D., svp, global head corporate and business development at Intercell. “In the beginning, big pharma controlled the value chain. Now biotechs can keep it for as long as possible and even bring vaccines to market as we have done this year with our Japanese Encephalitis vaccine.”

  • On Target for Success

    Click Image To Enlarge +
    A vaccibody is a three-component antibody-like molecule. (Vaccibody)

    Many biotechs at the “World Vaccine Congress” had plenty of innovation to shout about, including Vaccibody. This spin-out from the University of Oslo showed off a twist on antibody technology that helps target vaccines to boost T-cell immunity.

    “A vaccibody construct is a three-component antibody-like molecule,” Dr. Ole Henrik Brekke, Ph.D., CEO of Vaccibody, said. “It has a targeting unit that can be part of an antibody or binding ligand that attaches to surface molecules on antigen presenting cells (APC). The targeting unit is attached to a dimerization unit consisting of a hinge and CH3 domain from an immunoglobulin, so this section of the vaccibody even looks a bit like an antibody. Finally, the third part is the antigen or the vaccine unit.”

    “Vaccibodies work by binding surface molecules on APCs,” Dr. Brekke continued. “The complex is taken up, and antigenic peptides are presented to CD4 or CD8 cells. The CD4 T cells secrete cytokines that help B cells develop into plasma cells that secrete huge amounts of antibodies. The CD8 and CD4 T cells as well as the antibodies generated eliminate the infectious agent or tumor cells they have been targeted against.”

    To demonstrate proof of this concept, the company produced two types of vaccibodies containing pandemic flu and seasonal flu antigens. One is a normal targeting vaccibody and the other version has a mutation in the targeting unit so that it will not bind to APCs.

    Dr. Brekke presented mouse model data that showed 100 days after vaccination, the targeted vaccibody generated IgG levels five times higher than the nontargeting vaccibody. The CD8 and CD4 levels measured by ELISPOT were five to eight times higher (respectively) than the nontargeted vaccibody, showing that targeting the vaccibody does promote T-cell immunity.

    Additionally, 14 days after vaccination the mice injected with a vaccibody and challenged with a flu virus did not lose body weight compared to the unimmunized mice. The unimmunized mice showed drastically reduced weight and had to be sacrificed nine days after they were infected.

    “As long as you know the gene sequence of the antigen you can easily exchange the vaccine unit so this type of vaccibody platform could be used to produce prophylactic or therapeutic vaccines against a range of diseases,” Dr. Brekke stated. “Vaccibody technology offers good safety, stability, and efficacy. Now that we have preclinical proof the vaccibodies work well we are seeking partners that would like to license this technology.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?